Qiagen (NYSE:QGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 2.100- for the period, compared to the consensus estimate of 2.110. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of $2.0 billion. Qiagen also updated its FY24 guidance to at least $2.10 EPS.
Qiagen Price Performance
NYSE QGEN traded up $0.67 on Monday, reaching $42.32. 2,566,569 shares of the company’s stock traded hands, compared to its average volume of 1,200,973. The stock has a 50-day simple moving average of $42.58 and a 200 day simple moving average of $42.68. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.99 and a quick ratio of 1.62. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.70. The stock has a market cap of $9.66 billion, a PE ratio of 27.96, a P/E/G ratio of 3.51 and a beta of 0.41.
Qiagen (NYSE:QGEN – Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.55 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.55. Qiagen had a net margin of 17.37% and a return on equity of 12.99%. The company had revenue of $509.00 million during the quarter, compared to the consensus estimate of $500.77 million. During the same period in the prior year, the firm earned $0.53 earnings per share. As a group, research analysts predict that Qiagen will post 2.09 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Report on Qiagen
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
See Also
- Five stocks we like better than Qiagen
- How to Capture the Benefits of Dividend Increases
- The 3 Hottest Insiders Buys This Month
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- What Bulls and Bears May Be Getting Wrong about SOFI Stock
- 3 Monster Growth Stocks to Buy Now
- Microsoft Analysis: Trends, Predictions & Investment Insight
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.